Program overview
Context
Indication: Castration-Resistant Prostatic Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: MacroGenics
Registry Stop Signal
vobramitamab duocarmazine 2.0 mg (Arm A)
vobramitamab duocarmazine 2.0 mg (Arm A) is flagged as registry stop signal because public records show a registry stop signal, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 5/5
Timeline: 0/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 4/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT05551117
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT05551117 | Registry Stop Signal (TERMINATED) | None | Low Signal | rare_population_signal | strict_eligibility_signal |